Contributor Page
Smart & Biggar/Fetherstonhaugh
 
Email  |  Website  |  Articles
Contact Details
Tel: +1 416 5935514
Fax: +1 416 5911690
1100-150 York Street
Toronto
ON M5H 3S5
Canada
By David Schwartz, Jeff Leuschner
On December 1, 2018, the Canadian government released its proposed new Patent Rules in the Canada Gazette, Part I.
By Smart & Biggar/Fetherstonhaugh
For complete details about these proceedings, click here.
By Lynn Ing
A Federal Court Order has issued on a motion to strike brought by Sandoz in four actions relating to infringement of rituximab patents.
By Alice Tseng
In October 2018, the Canadian Agency for Drugs and Technologies in Health (CADTH) issued an interesting Environmental Scan on International Policies on the Appropriate Use of Biosimilar Drugs (Report).
By Tierney Deluzio
Supreme Court of Canada denies Eli Lilly leave to appeal in olanzapine section 8 damages action.
By Andrew Mandlsohn
We previously reported on proposed amendments to the Patented Medicines Regulations released on December 2, 2017.
By Brandon Heard, Lynn Ing
In an action by Apotex for compensation from Sanofi and Schering under the Ontario Statute of Monopolies, U.K. Statute of Monopolies and the Trade-marks Act ...
By Philip Lapin
After years of uncertainty, a date has been finally been set for the implementation of Canada's new trademark law.
By Mark Evans, Jennifer Ponton
Section 22 of the Canadian Trademarks Act, depreciation of a registered trademark's goodwill, is a potentially powerful yet generally under-utilized weapon for dealing with damaging comparative
By Christine Genge, Lionel Fishman
Today marks an important step in the evolution of the industrial design regime in Canada
By David Schwartz, Emily Miller
On October 29, 2018, the Canadian Government introduced Bill C-86, A second Act to implement certain provisions of the budget tabled in Parliament on February 27
By Smart & Biggar/Fetherstonhaugh
New Court Proceedings - October 2018
By Urszula Wojtyra
The Federal Court of Canada has refused Pfizer's motion to dismiss an action under the Patented Medicines (Notice of Compliance) Regulations (PMNOC Regulations) ...
By Tierney Deluzio
This motion arose in the context of a section 8 action in which Apotex claims damages for delay in the issuance of its notice of compliance for its generic lansoprazole product ...
By Mark Evans, Nora Labbancz
Non-Canadian hoteliers have reason for celebration following the release of the Federal Court of Canada's anticipated decision in Hilton Worldwide Holding LLP v Miller Thomson LLP, 2018 FC 895